The 4-Year Outcome of the ScanCLAD Study

Purpose: The ScanCLAD trial showed a significant lower incidence of chronic lung allograft dysfunction (CLAD) three years after lung transplantation (LTx) in recipients treated with tacrolimus compared to cyclosporine. We now determine CLAD and survival outcomes at four years follow-up.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , T. Kromann Lund, P. Raivio, I. Leuckfeld, J. Svahn, E.C. Holmberg, J. Magnusson Source Type: research